Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $50,084.16 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Well Van sold 6,168 shares of the company’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $8.12, for a total value of $50,084.16. Following the transaction, the insider owned 332,716 shares in the company, valued at $2,701,653.92. This trade represents a 1.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Well Daan Van also recently made the following trade(s):

• On Friday, September 11th, Well Van sold 6,168 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.63, for a total value of $47,061.84.

SOPHiA GENETICS Trading Down 3.1%

Shares of NASDAQ SOPH traded down $0.23 during trading on Wednesday, reaching $7.15. The stock had a trading volume of 432,750 shares, compared to its average volume of 308,157. The business’s 50-day moving average price is $7.82 and its 200-day moving average price is $6.12. SOPHiA GENETICS SA has a fifty-two week low of $3.75 and a fifty-two week high of $8.98. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. The company has a market cap of $599.81 million, a P/E ratio of -6.22 and a beta of 0.95.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its earnings results on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The firm had revenue of $23.31 million for the quarter, compared to analysts’ expectations of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. On average, equities research analysts predict that SOPHiA GENETICS SA will post -0.77 EPS for the current fiscal year.

Institutional Trading of SOPHiA GENETICS

Large investors have recently made changes to their positions in the company. First Dallas Securities Inc. acquired a new stake in SOPHiA GENETICS in the first quarter valued at approximately $50,000. Royal Bank of Canada grew its holdings in SOPHiA GENETICS by 3,130.2% during the 1st quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after acquiring an additional 18,781 shares in the last quarter. AXQ Capital LP acquired a new position in SOPHiA GENETICS during the 2nd quarter worth approximately $119,000. Silverberg Bernstein Capital Management LLC increased its position in shares of SOPHiA GENETICS by 8.7% in the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock valued at $257,000 after purchasing an additional 4,155 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. purchased a new stake in shares of SOPHiA GENETICS in the 2nd quarter valued at approximately $567,000. 31.59% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. HC Wainwright increased their price objective on SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Finally, BTIG Research lifted their target price on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, SOPHiA GENETICS has an average rating of “Hold” and a consensus price target of $10.00.

More SOPHiA GENETICS News

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Brokerages reportedly have a consensus price target of $10.00 for SOPHiA GENETICS, suggesting potential upside from recent trading levels if the company meets analyst expectations. SOPHiA GENETICS SA Stock Has Consensus Target Price of $10.00 According to Brokerages
• Neutral Sentiment: A comparison article examined SOPHiA GENETICS against Weave Communications, but the item did not identify a specific new company development or change to SOPH’s outlook. Critical Comparison: Weave Communications vs. SOPHiA GENETICS
• Negative Sentiment: Company insiders collectively sold approximately 82,298 shares worth $668,827, including sales by Chairman Jurgi Camblong, CEO Ross Muken, CFO George Cardoza, CTO Abhimanyu Verma and other executives. The transactions reduced their individual holdings by roughly 0.15% to 3.55%, creating near-term selling pressure and potentially weighing on investor sentiment. However, all reported sales were pre-arranged and explicitly made to satisfy tax obligations rather than indicating discretionary selling. SEC insider transaction filing

SOPHiA GENETICS Company Profile

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.